CN Patent

CN106604726A — 用于治疗史密斯‑马吉利综合征的他司美琼

Assigned to Vanda Pharmaceuticals Inc · Expires 2017-04-26 · 9y expired

What this patent protects

本发明的实施方式涉及患有史密斯‑马吉利综合征(SMS)的个体中的睡眠障碍的治疗。

USPTO Abstract

本发明的实施方式涉及患有史密斯‑马吉利综合征(SMS)的个体中的睡眠障碍的治疗。

Drugs covered by this patent

Patent Metadata

Patent number: CN106604726A
Jurisdiction: CN
Classification: —
Expires: 2017-04-26
Drug substance claim: No
Drug product claim: No
Assignee: Vanda Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.